Post by Oncode Accelerator

6,637 followers

๐˜ฝ๐™ช๐™ž๐™ก๐™™๐™ž๐™ฃ๐™œ ๐˜ฝ๐™ง๐™ž๐™™๐™œ๐™š๐™จ: ๐—ง๐—ฎ๐—ฟ๐—ด๐—ฒ๐˜ ๐—˜๐—ป๐—ด๐—ฎ๐—ด๐—ฒ๐—บ๐—ฒ๐—ป๐˜ ๐—ฃ๐—ฟ๐—ผ๐—ณ๐—ถ๐—น๐—ถ๐—ป๐—ด & ๐—”๐˜‚๐˜๐—ผ๐—ง๐—ฆ๐—” ๐—ณ๐—ผ๐—ฟ ๐—ฆ๐—บ๐—ฎ๐—น๐—น ๐— ๐—ผ๐—น๐—ฒ๐—ฐ๐˜‚๐—น๐—ฒ ๐——๐—ฟ๐˜‚๐—ด ๐——๐—ถ๐˜€๐—ฐ๐—ผ๐˜ƒ๐—ฒ๐—ฟ๐˜† Join theย next Oncode Accelerator webinar, whichย brings together two complementary approaches to de-risking early-stage drug development in oncology, with a focus on ๐˜€๐—บ๐—ฎ๐—น๐—น ๐—บ๐—ผ๐—น๐—ฒ๐—ฐ๐˜‚๐—น๐—ฒ๐˜€! โ€ฏ๐Ÿ—“๏ธ 6 October 2026 โฐ 16:00 - 17:00 CET ๐Ÿ“โ€ฏTeams Jennifer McCormack-Venhorst, Senior Scientist Integrator at TNO, will open with a presentation onย ๐˜ผ๐™ช๐™ฉ๐™ค๐™๐™Ž๐˜ผ: ๐™๐™–๐™จ๐™ฉ๐™š๐™ง ๐™๐™–๐™ง๐™œ๐™š๐™ฉ ๐™Ž๐™–๐™›๐™š๐™ฉ๐™ฎ ๐˜ฟ๐™š๐™˜๐™ž๐™จ๐™ž๐™ค๐™ฃ๐™จ ๐™›๐™ค๐™ง ๐˜ฟ๐™ง๐™ช๐™œ ๐˜ฟ๐™ž๐™จ๐™˜๐™ค๐™ซ๐™š๐™ง๐™ฎ, sharing TNO's AI-driven approach to automating target safety assessments. ๐Ÿ’กย She will make the case for why these assessments belong early in drug development pipelines, especially for smaller biotechs that often skip this step until it's too late. Anthe Janssen, Co-founder and CSO of Omivera and Assistant Professor at Universiteit Leiden, follows withย ๐™๐™–๐™ง๐™œ๐™š๐™ฉ ๐™€๐™ฃ๐™œ๐™–๐™œ๐™š๐™ข๐™š๐™ฃ๐™ฉ ๐™‹๐™ง๐™ค๐™›๐™ž๐™ก๐™ž๐™ฃ๐™œ ๐˜ผ๐™˜๐™ง๐™ค๐™จ๐™จ ๐˜พ๐™ค๐™ข๐™ฅ๐™ก๐™š๐™ญ ๐˜ฝ๐™ž๐™ค๐™ก๐™ค๐™œ๐™ž๐™˜๐™–๐™ก ๐™Ž๐™ฎ๐™จ๐™ฉ๐™š๐™ข๐™จ ๐™๐™จ๐™ž๐™ฃ๐™œ ๐˜พ๐™๐™š๐™ข๐™ž๐™˜๐™–๐™ก ๐™‹๐™ง๐™ค๐™ฉ๐™š๐™ค๐™ข๐™ž๐™˜๐™จ. ๏ปฟ๐Ÿ’กHe will address why selectivity profiling needs to move beyond biochemical assays into living-cell systems that better capture the complexity drug developers actually face. ๏ปฟ ๏ปฟFor more information and registrationย ๐Ÿ‘‰ย https://lnkd.in/eZFeSar8

Post content